ProQR Therapeutics N.V.
PRQR · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 2.63 | 0.08 | 0.73 | -2.27 |
| FCF Yield | -18.09% | 13.90% | -27.96% | -5.86% |
| EV / EBITDA | -3.18 | -1.91 | -3.10 | -5.91 |
| Quality | ||||
| ROIC | -22.38% | -30.17% | -42.06% | -30.43% |
| Gross Margin | 100.00% | 97.95% | 38.68% | 100.00% |
| Cash Conversion Ratio | 1.31 | -0.78 | 1.07 | 0.43 |
| Growth | ||||
| Revenue 3-Year CAGR | 73.91% | 69.61% | 51.72% | -11.61% |
| Free Cash Flow Growth | -287.40% | 129.15% | -161.23% | 44.78% |
| Safety | ||||
| Net Debt / EBITDA | 5.48 | 4.12 | 1.29 | 2.31 |
| Interest Coverage | -28.29 | -26.48 | -12.62 | -16.80 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 360.61 | 0.00 |
| Cash Conversion Cycle | 39.14 | -4,141.41 | 5,118.13 | 0.00 |